Researchers conducted a small, single-center study involving 12 patients experiencing acute gout flares. The team compared giving etanercept, a biologic drug, under the skin twice over five days against receiving methylprednisolone, a steroid, intravenously every day for the same period. Both groups received treatment for their pain and inflammation.
The results showed that all 12 patients treated with etanercept experienced rapid and substantial relief from pain and inflammatory responses. The effect was found to be comparable to the steroid treatment used for comparison. Secondary measures like CRP levels and pain scores also supported these findings.
No serious adverse events were reported during the five-day follow-up, and the drug was well-tolerated in this small group. While the study suggests etanercept might be an option for patients who cannot use standard therapies, the very small sample size limits what can be concluded. More large-scale research is needed to confirm safety and effectiveness before this could be considered a standard practice.
